Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

SIMPLE SUMMARY: Biomarkers able to predict response and toxicity upon regorafenib therapy for colorectal cancer (CRC) are critical for treatment choice, particularly relevant in fragile patients. Here, we validated for the first time 18 distinct microRNAs (miRNAs) detected in serum and primary tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Conde, Elisa, Earl, Julie, Crespo-Toro, Lorena, Blanco-Agudo, Carolina, Ramos-Muñoz, Edurne, Rodríguez-Serrano, E. Macarena, Martínez Ávila, Jose Carlos, Salinas-Muñoz, Laura, Serrano-Huertas, Silvia, Ferreiro, Reyes, Rodriguez-Garrote, Mercedes, Sainz, Bruno, Massuti, Bartomeu, Alfonso, Pilar García, Benavides, Manuel, Aranda, Enrique, García-Bermejo, María Laura, Carrato, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038427/
https://www.ncbi.nlm.nih.gov/pubmed/33916610
http://dx.doi.org/10.3390/cancers13071710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038427/
https://www.ncbi.nlm.nih.gov/pubmed/33916610
http://dx.doi.org/10.3390/cancers13071710

Ejemplares similares